Clinical trials and a real-world study have similarly demonstrated no differences in cardiac safety, measured by left ventricular ejection fraction, between patients with HER2+ early-stage breast cancer receiving biosimilar trastuzumab compared to reference trastuzumab [11,12,15]. This evidence concerns the gene ERBB2 and breast carcinoma.